ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
LENS ai ™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.
Article content
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENS ai ™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company's newly launched, HYFT pattern-patented AI-native vaccine discovery engine.
Article content
Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO commented, 'This breakthrough highlights a new frontier in AI-driven biology—where discovery is rooted in the biology of a virus itself. By confirming that our sequence-derived patented HYFT patterns match structural signatures across all dengue serotypes, we're setting the stage for a universal vaccine design framework. Ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. More importantly, the implications appear to stretch far beyond the dengue virus. This is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.'
Article content
Building on this success in dengue, IPA now intends to extend its AI-driven vaccine design platform to other high-impact infectious diseases, for example, HIV, Norovirus, and an improved RSV vaccine. Early-stage assessments are also underway to explore the platform's application in oncology for neoantigen vaccine development and tumor-specific epitope mapping.
Article content
This discovery underscores IPA's commitment to advancing drug discovery through innovative, human-relevant AI technologies that align with evolving industry standards. Using HYFT's patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the Company's proprietary LENS ai platform identified a unique epitope shared across all four serotypes of the dengue virus—DENV-1, DENV-2, DENV-3, and DENV-4. These serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design.
Article content
Why Has a Universal Dengue Vaccine Been So Elusive?
Article content
Dengue is not just one virus—it's four distinct, rapidly-evolving serotypes. Immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. For decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus's rapid mutation and complex immune interactions. Traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale.
Article content
Confirmed Breakthrough: Sequence and Structural HYFT Match Across All Four Serotypes
Article content
IPA's discovery is a landmark moment in computational vaccinology. Using its proprietary LENSai™ platform powered by their patented HYFT® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes— a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. This achievement marks a critical milestone in the quest for a universal dengue vaccine.
Article content
What sets this apart is the depth of validation:
Article content
Patented HYFT patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural HYFTs across all four dengue serotypes.
This was made possible through LENS ai 's integration of over 20 million proprietary Structural HYFTs (S-HYFTs), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints.
The validation demonstrates that LENS ai doesn't simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-EM.
Article content
This milestone affirms the patented HYFT technology's unique ability to traverse the full biological hierarchy—from DNA/RNA sequence to molecular structure to therapeutic relevance. It signals that AI-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research.
Article content
The end-to-end LENS ai platform integrates patented HYFT® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. The result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges.
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family').
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the LENS ai ™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery and vaccine development methods; the expansion of IPA's discovery engine to additional infectious disease and oncology targets; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum.
Article content
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions.
Article content
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Datadog (DDOG): New Buy Recommendation for This Technology Giant
Barclays analyst Raimo Lenschow maintained a Buy rating on Datadog on July 18 and set a price target of $170.00. The company's shares closed last Friday at $145.02. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Lenschow covers the Technology sector, focusing on stocks such as CoreWeave, Inc. Class A, Microsoft, and Oracle. According to TipRanks, Lenschow has an average return of 11.8% and a 60.76% success rate on recommended stocks. In addition to Barclays, Datadog also received a Buy from UBS's Karl Keirstead in a report issued on July 16. However, on July 10, Morgan Stanley maintained a Hold rating on Datadog (NASDAQ: DDOG). Based on Datadog's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $761.55 million and a net profit of $24.64 million. In comparison, last year the company earned a revenue of $611.25 million and had a net profit of $42.63 million Based on the recent corporate insider activity of 142 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DDOG in relation to earlier this year. Last month, Olivier Pomel, the CEO of DDOG sold 15,227.00 shares for a total of $1,779,122.68.
Globe and Mail
2 hours ago
- Globe and Mail
Tesla Inc: Analysts Update Target Forecasts
Tesla Inc. (TSLA) (TSLA:CA) Bank of America (BofA) has increased its 12-month price target on Tesla Inc. from $305 to $341, reflecting a more optimistic outlook for the electric vehicle maker's potential. Despite the raised target, BofA has maintained its 'Neutral' rating, signaling that while the bank acknowledges improving fundamentals or external conditions (such as macro trends, cost efficiencies, or AI/data center tailwinds), it believes the stock is fairly valued at current levels. The 'Neutral' stance suggests a balanced view of upside and downside risks amid ongoing concerns like increased competition, regulatory uncertainty, and potential volatility around deliveries and margins. Cantor Fitzgerald has reiterated its 'Overweight' rating on Tesla and maintained its 12 month price target of $355 per share, indicating continued confidence in Tesla's growth trajectory and long-term value. The Overweight rating implies that Cantor expects Tesla to outperform the broader market and sector average. Cantor likely sees strength in Tesla's expanding product pipeline, leadership in EV technology, and potential upside from its AI and robotics ventures—such as Full Self-Driving (FSD) and Optimus—justifying a higher valuation multiple. Stock Forecast & Analysis Tesla's consensus analyst rating is a 'Hold', reflecting a mixed sentiment on the stock. The average 12-month price target for Tesla stands at approximately $300 per share, suggesting the stock is currently trading over over its perceived valuation models. The consensus target reflects analyst expectations factoring in the company's fundamentals, competitive environment, and broader macroeconomic conditions. Key contributors to this Hold consensus include: Concerns over valuation: Tesla trades at a premium relative to traditional automakers, and many analysts believe the stock price already reflects aggressive growth assumptions. Competition and market saturation: Analysts are watching how Tesla will fare as legacy automakers and new EV startups increase competition, especially in core markets like the U.S., China, and Europe. Margin pressures: Ongoing price cuts, high R&D spending on AI and robotics, and ramp-up costs for new models or facilities could weigh on margins, limiting near-term earnings growth. Catalysts for future upside: Some analysts remain optimistic about long-term catalysts including Tesla's progress in Full Self-Driving (FSD) technology, expansion into energy storage, potential monetization of AI-related assets, and new vehicle platforms.
Globe and Mail
4 hours ago
- Globe and Mail
Faraday Future Partners with HabitTrade to Accelerate its Entry into the Web3 Financial Ecosystem
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or the 'Company'), a California-based global shared intelligent electric mobility ecosystem company, today announced its strategic collaboration with HabitTrade, a global multi-market brokerage and digital asset infrastructure platform. This collaboration marks Faraday Future's first step into the Web3 financial ecosystem, and is supported by RWA Group ( a digital finance advisory firm. This press release features multimedia. View the full release here: Faraday Future Partners with HabitTrade to Accelerate its Entry into the Web3 Financial Ecosystem As Faraday Future expands its vision beyond mobility into the next frontier of finance, the partnership with HabitTrade aims to unlock new possibilities in Web3 capital markets—including stablecoin-based investment, native digital asset flows, and broader participation from decentralized communities. This collaboration is also a key part of Faraday Future's ongoing commitment to technological and capital infrastructure innovation. Notably, Faraday Future plans to leverage this partnership to offer exclusive HabitTrade platform benefits to its shareholders, further enhancing shareholder value through innovative Web3 financial services. 'This partnership with HabitTrade is a key milestone in our efforts to connect Faraday Future with the Web3 financial world,' said Jerry Wang, Global President of Faraday Future. 'As we continue to redefine intelligent mobility, we are also exploring how decentralized infrastructure and digital asset participation can bring greater value to our stakeholders and communities.' 'We are honored to partner with Faraday Future in building its entry into the Web3 finance space,' said Daniel, Founder of HabitTrade. 'This collaboration is more than a cross-industry initiative — it reflects a shared belief in financial accessibility, technological innovation, and the long-term potential of decentralized capital markets. As a platform that bridges traditional and crypto finance, HabitTrade will provide the infrastructure and global liquidity support needed to help forward-looking enterprises like Faraday Future embrace the next evolution of finance.' Tony Fu, Founder of RWA Group, added: 'As a Nasdaq-listed EV company, Faraday Future is not only leading innovation in intelligent mobility but also actively shaping the path from Web2 to Web3. We're pleased to support this initiative and believe more listed companies will follow suit in embracing Web3-native tools such as tokenized assets, digital issuance, and cross-border financial connectivity.' This collaboration underscores a growing convergence between traditional industry leaders and next-generation financial platforms, as more enterprises begin to leverage Web3 capabilities to unlock new value. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF 91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit ABOUT HABITTRADE HabitTrade is a global multi-market brokerage and infrastructure platform that enables stablecoin-based access to a wide range of financial products—including U.S. and Hong Kong stocks, ETFs, and crypto assets. In addition to serving individual investors, HabitTrade provides institutional services such as API connectivity and market entry solutions for IPOs, tokenization projects, and more—helping bridge the gap between traditional and Web3 capital markets. ABOUT RWA GROUP ( Based in Hong Kong Science Park, RWA Group (formerly NFT China) specializes in digital finance advisory and infrastructure services. With a team experienced in blockchain, capital markets, and asset tokenization, RWA Group supports traditional enterprises in exploring Web3 innovations such as digital issuance, compliance frameworks, and real-world asset integration. FORWARD LOOKING STATEMENTS This press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company's ability to secure necessary agreements to license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to secure necessary permits at its Hanford, CA production facility; the Company's ability to secure regulatory approvals for the proposed Super One front grill; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to cover future warranty claims; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
